Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies
SLEEP · 2024
DOI: 10.1093/sleep/zsae098 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift SLEEP, 2024. Verfasst von Tobias Di Marco und 14 weiteren Autor:innen. Beteiligte Einrichtung: Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Electroencephalography. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Study Objectives Post hoc analysis to evaluate the effect of daridorexant on sleep architecture in people with insomnia, focusing on features associated with hyperarousal.
Methods
We studied sleep architecture in adults with chronic insomnia disorder from two randomized phase 3 clinical studies (Clinicaltrials.gov: NCT03545191 and NCT03575104) investigating 3 months of daridorexant treatment (placebo, daridorexant 25 mg, daridorexant 50 mg). We analyzed sleep–wake transition probabilities, EEG spectra, and sleep spindle properties including density, dispersion, and slow oscillation phase coupling. The wake EEG similarity index (WESI) was determined using a machine learning algorithm analyzing the spectral profile of the EEG.
Results
At month 3, daridorexant 50 mg decreased wake-to-wake transition probabilities (p < .05) and increased the probability of transitions from wake-to-N1 (p < .05), N2 (p < .05), and REM sleep (p < .05), as well as from N1-to-N2 (p < .05) compared to baseline and placebo. Daridorexant 50 mg decreased relative beta power during wake (p = .011) and N1 (p < .001) compared to baseline and placebo. During the wake, relative alpha power decreased (p < .001) and relative delta power increased (p < .001) compared to placebo. Daridorexant did not alter EEG spectra bands in N2, N3, and REM stages or in sleep spindle activity. Daridorexant decreased the WESI score during wake compared to baseline (p = .004). Effects with 50 mg were consistent between months 1 and 3 and less pronounced with 25 mg.
Conclusions
Daridorexant reduced EEG features associated with hyperarousal as indicated by reduced wake-to-wake transition probabilities and enhanced spectral features associated with drowsiness and sleep during wake and N1. Clinical Trials ClinicalTrials.gov NCT03545191: study to assess the efficacy and safety of ACT-541468 (daridorexant) in adult and elderly participants with insomnia disorder. URL: Study Details | study to assess the efficacy and safety of ACT-541468 (daridorexant) in adult and elderly participants with insomnia disorder | ClinicalTrials.gov ClinicalTrials.gov NCT03575104: study to assess the efficacy and safety of ACT-541468 (daridorexant) in adult and elderly participants who experience difficulties sleeping. URL: study details | study to assess the efficacy and safety of ACT-541468 (daridorexant) in adult and elderly participants who experience difficulties sleeping | ClinicalTrials.gov
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
- Department of Clinical Research, University of Basel, Schanzenstrasse, Basel.
- Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- Centre National de Référence Narcolepsie, Unité du Sommeil, CHU Montpellier, Hôpital Gui-de-Chauliac, Université de Montpellier, INSERM INM, Montpellier, France.
- Beacon Biosignals, Inc., Boston, MA, USA.
- Zentrum für Schlaf- und Chronomedizin der Basler Universitätskliniken, University Children's Hospital Basel, Basel, Switzerland.
ORCID-Profile: Yves Dauvilliers, Liborio Parrino
Zitieren
APA
Di Marco, T., Djonlagic, I., Dauvilliers, Y., Sadeghi, K., Little, D., Datta, A. N., Hubbard, J., Hajak, G., Krystal, A., Olivieri, A., Parrino, L., Puryear, C. B., Zammit, G., Donoghue, J., & Scammell, T. E. (2024). Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies. SLEEP. https://doi.org/10.1093/sleep/zsae098
Vancouver
Di Marco T, Djonlagic I, Dauvilliers Y, Sadeghi K, Little D, Datta AN, et al. Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies. SLEEP. 2024. doi:10.1093/sleep/zsae098
BibTeX
@article{DiMarco2024,
author = {Di Marco, Tobias and Djonlagic, Ina and Dauvilliers, Yves and Sadeghi, Kolia and Little, David and Datta, Alexandre N and Hubbard, Jeffrey and Hajak, Göran and Krystal, Andrew and Olivieri, Antonio and Parrino, Liborio and Puryear, Corey B and Zammit, Gary and Donoghue, Jacob and Scammell, Thomas E},
title = {Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies},
journal = {SLEEP},
year = {2024},
doi = {10.1093/sleep/zsae098}
}
EUVIMED